---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-009384"
form_type: "8-K"
ticker: "IDXG"
cik: "0001054102"
company_name: "INTERPACE BIOSCIENCES, INC."
filed_at: "2025-03-06T23:59:59+00:00"
generated_at: "2026-05-25T04:48:58.603761+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Interpace Biosciences to restate 2023 and quarterly 2023/2024 financials due to accrued royalty errors

## Summary
- Accrued royalties overstated by $5.3M to $7.1M across 2023 and 2024 quarterly balance sheets.
- Restatement expected to reduce liabilities and increase net income; revenues and cash flows unchanged.
- Non-reliance on financial statements for FY2023, Q1-Q3 2023 and Q1-Q3 2024.
- Management will report a material weakness in internal controls over accrued royalty assessment.
- Cumulative impact from 2015-2022 is $4.8M aggregate; no restatement for periods before 2023.

## SEC filing metadata
- accession: 0001493152-25-009384
- form_type: 8-K
- ticker: IDXG
- cik: 0001054102
- company_name: INTERPACE BIOSCIENCES, INC.
- filed_at: 2025-03-06T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 4.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1054102/000149315225009384/0001493152-25-009384-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1054102/000149315225009384/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-009384
- JSON: https://secwatch.observer/filing/0001493152-25-009384.json
- Plain text: https://secwatch.observer/filing/0001493152-25-009384.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.